Immix Biopharma, Inc. IMMX Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s weighted average exercise price of outstanding options?
- Immix Biopharma, Inc. (IMMX) reported weighted average exercise price of outstanding options of $2.33 in Q1 2026.
- How has Immix Biopharma, Inc.'s weighted average exercise price of outstanding options changed year-over-year?
- Immix Biopharma, Inc.'s weighted average exercise price of outstanding options increased by 15.3% year-over-year, from $2.02 to $2.33.
- What is the long-term trend for Immix Biopharma, Inc.'s weighted average exercise price of outstanding options?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s weighted average exercise price of outstanding options has grown at a 10.6% compound annual growth rate (CAGR), from $1.33 to $2.20.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.